Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Fisher & Paykel Healthcare Corporation Limited ( (FSPKF) ) is now available.
The United States has announced a new tariff regime imposing a 25% tariff on products imported from Mexico and Canada, and a 10% tariff on those from China, effective from February 4, 2025. Fisher & Paykel Healthcare, which manufactures a significant portion of its products in Mexico, anticipates increased costs for the 2026 financial year due to these tariffs. Although not expecting an immediate impact on their 2025 net profit, the company acknowledges potential challenges in reaching their gross margin target due to the tariffs, possibly extending the timeframe by two to three years. The company is working on strategies to mitigate the impact and will update stakeholders at the full year results announcement in May.
More about Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare is a prominent designer, manufacturer, and marketer of products and systems used in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea. The company’s products are distributed in over 120 countries globally.
YTD Price Performance: -17.23%
Average Trading Volume: 2,336
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.46B
See more insights into FSPKF stock on TipRanks’ Stock Analysis page.
